Industry Research Reports

Home > Reports > Medical Care > Noninvasive Cancer Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Noninvasive Cancer Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-24

Pages: 112 Pages

Report ld: 2333878

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to genetic alteration of the cells and therefore causing uncontrolled growth and forming tumor like structure. Imaging is the preferred method of cancer detection but cannot have genetic access; on the other hand biopsies which have genetic access are complicated and difficult to perform repetitively during the course of cancer diagnosis and therapy. Therefore newer techniques developed in lines with non invasive diagnosis such as molecular diagnosis, serum based immunoassays and chemical tests to identify chemical components in the body especially from blood and urine. All these procedures are performed either with non-surgical or minimal surgical procedures; therefore these non-invasive cancer diagnostic techniques are becoming more and more popular among healthcare practitioners.

The global market for Noninvasive Cancer Diagnostics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Noninvasive Cancer Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Noninvasive Cancer Diagnostics by region & country, by Type, and by Application.

The Noninvasive Cancer Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Cancer Diagnostics.

Market Segmentation

Report Metric
Details
Report Title
Noninvasive Cancer Diagnostics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Noninvasive Cancer Diagnostics Companies Covered
Precision Therapeutics, Inc. (U.S.), A&G Pharmaceutical, Inc. (U.S.), Affymetrix Inc. (U.S.), AVIVA Biosciences Corporation (U.S.), BIOVIEW Inc. (U.S.), Laboratory Corporation of America Holdings (LabCorp) (U.S.), Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.), Digene Corporation (U.S.), Gen-Probe Incorporated (U.S.), IVDiagnostics, Inc. (U.S.)
Global Noninvasive Cancer Diagnostics Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Noninvasive Cancer Diagnostics Market, Segment by Type
Clinical Chemistry

Immunochemistry/Immunoassay

Molecular Diagnostics

Others
Global Noninvasive Cancer Diagnostics Market, Segment by Application
Solid Tumors

Blood Cancer

Lung Cancer

Breast Cancer

Others
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Noninvasive Cancer Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Noninvasive Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Noninvasive Cancer Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Noninvasive Cancer Diagnostics Product Introduction
    1.2 Global Noninvasive Cancer Diagnostics Market Size Forecast
    1.3 Noninvasive Cancer Diagnostics Market Trends & Drivers
        1.3.1 Noninvasive Cancer Diagnostics Industry Trends
        1.3.2 Noninvasive Cancer Diagnostics Market Drivers & Opportunity
        1.3.3 Noninvasive Cancer Diagnostics Market Challenges
        1.3.4 Noninvasive Cancer Diagnostics Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Noninvasive Cancer Diagnostics Players Revenue Ranking (2023)
    2.2 Global Noninvasive Cancer Diagnostics Revenue by Company (2019-2024)
    2.3 Key Companies Noninvasive Cancer Diagnostics Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Noninvasive Cancer Diagnostics Product Offered
    2.5 Key Companies Time to Begin Mass Production of Noninvasive Cancer Diagnostics
    2.6 Noninvasive Cancer Diagnostics Market Competitive Analysis
        2.6.1 Noninvasive Cancer Diagnostics Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Noninvasive Cancer Diagnostics Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Clinical Chemistry
        3.1.2 Immunochemistry/Immunoassay
        3.1.3 Molecular Diagnostics
        3.1.4 Others
    3.2 Global Noninvasive Cancer Diagnostics Sales Value by Type
        3.2.1 Global Noninvasive Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Noninvasive Cancer Diagnostics Sales Value, by Type (2019-2030)
        3.2.3 Global Noninvasive Cancer Diagnostics Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Solid Tumors
        4.1.2 Blood Cancer
        4.1.3 Lung Cancer
        4.1.4 Breast Cancer
        4.1.5 Others
    4.2 Global Noninvasive Cancer Diagnostics Sales Value by Application
        4.2.1 Global Noninvasive Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Noninvasive Cancer Diagnostics Sales Value, by Application (2019-2030)
        4.2.3 Global Noninvasive Cancer Diagnostics Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Noninvasive Cancer Diagnostics Sales Value by Region
        5.1.1 Global Noninvasive Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Noninvasive Cancer Diagnostics Sales Value by Region (2019-2024)
        5.1.3 Global Noninvasive Cancer Diagnostics Sales Value by Region (2025-2030)
        5.1.4 Global Noninvasive Cancer Diagnostics Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        5.2.2 North America Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        5.3.2 Europe Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        5.4.2 Asia Pacific Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        5.5.2 South America Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        5.6.2 Middle East & Africa Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Noninvasive Cancer Diagnostics Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Noninvasive Cancer Diagnostics Sales Value
    6.3 United States
        6.3.1 United States Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        6.3.2 United States Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Noninvasive Cancer Diagnostics Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        6.4.2 Europe Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Noninvasive Cancer Diagnostics Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        6.5.2 China Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Noninvasive Cancer Diagnostics Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        6.6.2 Japan Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Noninvasive Cancer Diagnostics Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        6.7.2 South Korea Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Noninvasive Cancer Diagnostics Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        6.8.2 Southeast Asia Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Noninvasive Cancer Diagnostics Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Noninvasive Cancer Diagnostics Sales Value, 2019-2030
        6.9.2 India Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Noninvasive Cancer Diagnostics Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Precision Therapeutics, Inc. (U.S.)
        7.1.1 Precision Therapeutics, Inc. (U.S.) Profile
        7.1.2 Precision Therapeutics, Inc. (U.S.) Main Business
        7.1.3 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.1.4 Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.1.5 Precision Therapeutics, Inc. (U.S.) Recent Developments
    7.2 A&G Pharmaceutical, Inc. (U.S.)
        7.2.1 A&G Pharmaceutical, Inc. (U.S.) Profile
        7.2.2 A&G Pharmaceutical, Inc. (U.S.) Main Business
        7.2.3 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.2.4 A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.2.5 A&G Pharmaceutical, Inc. (U.S.) Recent Developments
    7.3 Affymetrix Inc. (U.S.)
        7.3.1 Affymetrix Inc. (U.S.) Profile
        7.3.2 Affymetrix Inc. (U.S.) Main Business
        7.3.3 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.3.4 Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.3.5 AVIVA Biosciences Corporation (U.S.) Recent Developments
    7.4 AVIVA Biosciences Corporation (U.S.)
        7.4.1 AVIVA Biosciences Corporation (U.S.) Profile
        7.4.2 AVIVA Biosciences Corporation (U.S.) Main Business
        7.4.3 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.4.4 AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.4.5 AVIVA Biosciences Corporation (U.S.) Recent Developments
    7.5 BIOVIEW Inc. (U.S.)
        7.5.1 BIOVIEW Inc. (U.S.) Profile
        7.5.2 BIOVIEW Inc. (U.S.) Main Business
        7.5.3 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.5.4 BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.5.5 BIOVIEW Inc. (U.S.) Recent Developments
    7.6 Laboratory Corporation of America Holdings (LabCorp) (U.S.)
        7.6.1 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Profile
        7.6.2 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Main Business
        7.6.3 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.6.4 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.6.5 Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Developments
    7.7 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
        7.7.1 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Profile
        7.7.2 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Main Business
        7.7.3 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.7.4 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.7.5 Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Developments
    7.8 Digene Corporation (U.S.)
        7.8.1 Digene Corporation (U.S.) Profile
        7.8.2 Digene Corporation (U.S.) Main Business
        7.8.3 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.8.4 Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.8.5 Digene Corporation (U.S.) Recent Developments
    7.9 Gen-Probe Incorporated (U.S.)
        7.9.1 Gen-Probe Incorporated (U.S.) Profile
        7.9.2 Gen-Probe Incorporated (U.S.) Main Business
        7.9.3 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.9.4 Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.9.5 Gen-Probe Incorporated (U.S.) Recent Developments
    7.10 IVDiagnostics, Inc. (U.S.)
        7.10.1 IVDiagnostics, Inc. (U.S.) Profile
        7.10.2 IVDiagnostics, Inc. (U.S.) Main Business
        7.10.3 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
        7.10.4 IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Revenue (US$ Million) & (2019-2024)
        7.10.5 IVDiagnostics, Inc. (U.S.) Recent Developments

 8 Industry Chain Analysis
    8.1 Noninvasive Cancer Diagnostics Industrial Chain
    8.2 Noninvasive Cancer Diagnostics Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Noninvasive Cancer Diagnostics Sales Model
        8.5.2 Sales Channel
        8.5.3 Noninvasive Cancer Diagnostics Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Noninvasive Cancer Diagnostics Market Trends
    Table 2. Noninvasive Cancer Diagnostics Market Drivers & Opportunity
    Table 3. Noninvasive Cancer Diagnostics Market Challenges
    Table 4. Noninvasive Cancer Diagnostics Market Restraints
    Table 5. Global Noninvasive Cancer Diagnostics Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Noninvasive Cancer Diagnostics Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Noninvasive Cancer Diagnostics Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Noninvasive Cancer Diagnostics Product Type
    Table 9. Key Companies Time to Begin Mass Production of Noninvasive Cancer Diagnostics
    Table 10. Global Noninvasive Cancer Diagnostics Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Noninvasive Cancer Diagnostics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Noninvasive Cancer Diagnostics Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Noninvasive Cancer Diagnostics Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Noninvasive Cancer Diagnostics Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Noninvasive Cancer Diagnostics Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Noninvasive Cancer Diagnostics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Noninvasive Cancer Diagnostics Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Noninvasive Cancer Diagnostics Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Noninvasive Cancer Diagnostics Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Noninvasive Cancer Diagnostics Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Noninvasive Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Noninvasive Cancer Diagnostics Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Noninvasive Cancer Diagnostics Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Noninvasive Cancer Diagnostics Sales Value by Region (2019-2024) & (%)
    Table 27. Global Noninvasive Cancer Diagnostics Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Noninvasive Cancer Diagnostics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Noninvasive Cancer Diagnostics Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Noninvasive Cancer Diagnostics Sales Value, (2025-2030) & (US$ Million)
    Table 31. Precision Therapeutics, Inc. (U.S.) Basic Information List
    Table 32. Precision Therapeutics, Inc. (U.S.) Description and Business Overview
    Table 33. Precision Therapeutics, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Precision Therapeutics, Inc. (U.S.) (2019-2024)
    Table 35. Precision Therapeutics, Inc. (U.S.) Recent Developments
    Table 36. A&G Pharmaceutical, Inc. (U.S.) Basic Information List
    Table 37. A&G Pharmaceutical, Inc. (U.S.) Description and Business Overview
    Table 38. A&G Pharmaceutical, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of A&G Pharmaceutical, Inc. (U.S.) (2019-2024)
    Table 40. A&G Pharmaceutical, Inc. (U.S.) Recent Developments
    Table 41. Affymetrix Inc. (U.S.) Basic Information List
    Table 42. Affymetrix Inc. (U.S.) Description and Business Overview
    Table 43. Affymetrix Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Affymetrix Inc. (U.S.) (2019-2024)
    Table 45. Affymetrix Inc. (U.S.) Recent Developments
    Table 46. AVIVA Biosciences Corporation (U.S.) Basic Information List
    Table 47. AVIVA Biosciences Corporation (U.S.) Description and Business Overview
    Table 48. AVIVA Biosciences Corporation (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of AVIVA Biosciences Corporation (U.S.) (2019-2024)
    Table 50. AVIVA Biosciences Corporation (U.S.) Recent Developments
    Table 51. BIOVIEW Inc. (U.S.) Basic Information List
    Table 52. BIOVIEW Inc. (U.S.) Description and Business Overview
    Table 53. BIOVIEW Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of BIOVIEW Inc. (U.S.) (2019-2024)
    Table 55. BIOVIEW Inc. (U.S.) Recent Developments
    Table 56. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Basic Information List
    Table 57. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Description and Business Overview
    Table 58. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Laboratory Corporation of America Holdings (LabCorp) (U.S.) (2019-2024)
    Table 60. Laboratory Corporation of America Holdings (LabCorp) (U.S.) Recent Developments
    Table 61. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Basic Information List
    Table 62. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Description and Business Overview
    Table 63. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) (2019-2024)
    Table 65. Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.) Recent Developments
    Table 66. Digene Corporation (U.S.) Basic Information List
    Table 67. Digene Corporation (U.S.) Description and Business Overview
    Table 68. Digene Corporation (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Digene Corporation (U.S.) (2019-2024)
    Table 70. Digene Corporation (U.S.) Recent Developments
    Table 71. Gen-Probe Incorporated (U.S.) Basic Information List
    Table 72. Gen-Probe Incorporated (U.S.) Description and Business Overview
    Table 73. Gen-Probe Incorporated (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of Gen-Probe Incorporated (U.S.) (2019-2024)
    Table 75. Gen-Probe Incorporated (U.S.) Recent Developments
    Table 76. IVDiagnostics, Inc. (U.S.) Basic Information List
    Table 77. IVDiagnostics, Inc. (U.S.) Description and Business Overview
    Table 78. IVDiagnostics, Inc. (U.S.) Noninvasive Cancer Diagnostics Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Noninvasive Cancer Diagnostics Business of IVDiagnostics, Inc. (U.S.) (2019-2024)
    Table 80. IVDiagnostics, Inc. (U.S.) Recent Developments
    Table 81. Key Raw Materials Lists
    Table 82. Raw Materials Key Suppliers Lists
    Table 83. Noninvasive Cancer Diagnostics Downstream Customers
    Table 84. Noninvasive Cancer Diagnostics Distributors List
    Table 85. Research Programs/Design for This Report
    Table 86. Key Data Information from Secondary Sources
    Table 87. Key Data Information from Primary Sources
    Table 88. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Noninvasive Cancer Diagnostics Product Picture
    Figure 2. Global Noninvasive Cancer Diagnostics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Noninvasive Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
    Figure 4. Noninvasive Cancer Diagnostics Report Years Considered
    Figure 5. Global Noninvasive Cancer Diagnostics Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Noninvasive Cancer Diagnostics Revenue in 2023
    Figure 7. Noninvasive Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Clinical Chemistry Picture
    Figure 9. Immunochemistry/Immunoassay Picture
    Figure 10. Molecular Diagnostics Picture
    Figure 11. Others Picture
    Figure 12. Global Noninvasive Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 13. Global Noninvasive Cancer Diagnostics Sales Value Market Share by Type, 2023 & 2030
    Figure 14. Product Picture of Solid Tumors
    Figure 15. Product Picture of Blood Cancer
    Figure 16. Product Picture of Lung Cancer
    Figure 17. Product Picture of Breast Cancer
    Figure 18. Product Picture of Others
    Figure 19. Global Noninvasive Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 20. Global Noninvasive Cancer Diagnostics Sales Value Market Share by Application, 2023 & 2030
    Figure 21. North America Noninvasive Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
    Figure 22. North America Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    Figure 23. Europe Noninvasive Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
    Figure 24. Europe Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    Figure 25. Asia Pacific Noninvasive Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
    Figure 26. Asia Pacific Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    Figure 27. South America Noninvasive Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
    Figure 28. South America Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    Figure 29. Middle East & Africa Noninvasive Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
    Figure 30. Middle East & Africa Noninvasive Cancer Diagnostics Sales Value by Country (%), 2023 VS 2030
    Figure 31. Key Countries/Regions Noninvasive Cancer Diagnostics Sales Value (%), (2019-2030)
    Figure 32. United States Noninvasive Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)
    Figure 33. United States Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
    Figure 34. United States Noninvasive Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030
    Figure 35. Europe Noninvasive Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)
    Figure 36. Europe Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
    Figure 37. Europe Noninvasive Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030
    Figure 38. China Noninvasive Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)
    Figure 39. China Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
    Figure 40. China Noninvasive Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030
    Figure 41. Japan Noninvasive Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)
    Figure 42. Japan Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
    Figure 43. Japan Noninvasive Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030
    Figure 44. South Korea Noninvasive Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)
    Figure 45. South Korea Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
    Figure 46. South Korea Noninvasive Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030
    Figure 47. Southeast Asia Noninvasive Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)
    Figure 48. Southeast Asia Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
    Figure 49. Southeast Asia Noninvasive Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030
    Figure 50. India Noninvasive Cancer Diagnostics Sales Value, (2019-2030) & (US$ Million)
    Figure 51. India Noninvasive Cancer Diagnostics Sales Value by Type (%), 2023 VS 2030
    Figure 52. India Noninvasive Cancer Diagnostics Sales Value by Application (%), 2023 VS 2030
    Figure 53. Noninvasive Cancer Diagnostics Industrial Chain
    Figure 54. Noninvasive Cancer Diagnostics Manufacturing Cost Structure
    Figure 55. Channels of Distribution (Direct Sales, and Distribution)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation

Description

Non-invasive diagnosis is a procedure of identifying a disease without or with minimal incision of the body. These methods involve different techniques such as identifying genetic structure, biomarkers, changes in molecular biology, along with imaging technologies. Cancer is a disease related to genetic alteration of the cells and therefore causing uncontrolled growth and forming tumor like structure. Imaging is the preferred method of cancer detection but cannot have genetic access; on the other hand biopsies which have genetic access are complicated and difficult to perform repetitively during the course of cancer diagnosis and therapy. Therefore newer techniques developed in lines with non invasive diagnosis such as molecular diagnosis, serum based immunoassays and chemical tests to identify chemical components in the body especially from blood and urine. All these procedures are performed either with non-surgical or minimal surgical procedures; therefore these non-invasive cancer diagnostic techniques are becoming more and more popular among healthcare practitioners.

The global market for Noninvasive Cancer Diagnostics was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

Market Segmentation